Seguir
Michael C Kann
Michael C Kann
Otros nombresMichael Kann, Michael Charles Kann
Cellular Immunotherapy Program, Massachusetts General Hospital
Dirección de correo verificada de mgh.harvard.edu
Título
Citado por
Citado por
Año
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours
RC Larson, MC Kann, SR Bailey, NJ Haradhvala, PM Llopis, AA Bouffard, ...
Nature 604 (7906), 563-570, 2022
1872022
Reversible ON-and OFF-switch chimeric antigen receptors controlled by lenalidomide
M Jan, I Scarfò, RC Larson, A Walker, A Schmidts, AA Guirguis, JA Gasser, ...
Science translational medicine 13 (575), eabb6295, 2021
1642021
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
NJ Haradhvala, MB Leick, K Maurer, SH Gohil, RC Larson, N Yao, ...
Nature medicine 28 (9), 1848-1859, 2022
992022
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia
MB Leick, H Silva, I Scarfò, R Larson, BD Choi, AA Bouffard, K Gallagher, ...
Cancer cell 40 (5), 494-508. e5, 2022
642022
Blockade or deletion of IFNγ reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies
SR Bailey, S Vatsa, RC Larson, AA Bouffard, I Scarfò, MC Kann, ...
Blood Cancer Discovery 3 (2), 136-153, 2022
582022
Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2
BA Trombetta, SE Kandigian, RR Kitchen, K Grauwet, PK Webb, GA Miller, ...
BMC infectious diseases 21 (1), 580, 2021
242021
Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources
A Schmidts, LC Marsh, AA Srivastava, AA Bouffard, AC Boroughs, I Scarfò, ...
Journal for immunotherapy of cancer 8 (2), 2020
202020
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma
A Schmidts, AA Srivastava, R Ramapriyan, SR Bailey, AA Bouffard, ...
Neuro-Oncology Advances 5 (1), vdac185, 2023
132023
Effects of prior exposure to Tec kinase (BTK/ITK) inhibitors on Kte-X19 products
I Scarfò, KME Gallagher, MB Leick, MC Kann, J Budka, B Sowrirajan, ...
Blood 138, 3849, 2021
42021
Genetic retargeting of E3 ligases to enhance CAR T cell therapy
IC Lane, G Kembuan, J Carreiro, MC Kann, W Lin, AA Bouffard, J Kreuzer, ...
Cell Chemical Biology 31 (2), 338-348. e5, 2024
22024
Novel anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
RC Larson, A Castano, AA Bouffard, MC Kann, A Schmidts, KM Gallagher, ...
Cancer Research 82 (12_Supplement), 556-556, 2022
22022
Rational chemical and genetic modifications enhance avidity and function of CD70-directed CAR-T-cells for myeloid leukemia
MB Leick, H Silva, I Scarfò, R Larson, BD Choi, AA Bouffard, ...
Blood 138, 405, 2021
22021
Bispecific CAR T cells for multiple myeloma: natural ligand compared to tandem scFv design
R Larson, A Castano, A Bouffard, I Scarfo, M Kann, A Schmidts, ...
The Journal of Immunology 204 (1_Supplement), 246.3-246.3, 2020
22020
Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7
MC Kann, EM Schneider, AJ Almazan, IC Lane, AA Bouffard, VM Supper, ...
Leukemia 38 (3), 590-600, 2024
12024
Chimeric antigen receptor (CAR) T cells overexpressing Bcl-xL increase proliferation and antitumor activity alone and in combination with BH3 mimetics
F Korell, M Olson, D Salas-Benito, MB Leick, RC Larson, H Silva, ...
Cancer Research 83 (7_Supplement), 4098-4098, 2023
12023
767 interferon gamma reduces CAR-T exhaustion and toxicity without compromising therapeutic efficacy in hematologic malignancies
S Bailey, S Vatsa, A Bouffard, R Larson, I Scarfo, M Kann, A Schmidts, ...
Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020
12020
Interferon gamma reduces CAR-T exhaustion and toxicity without compromising therapeutic efficacy in hematologic malignancies
S Bailey, S Vatsa, A Bouffard, R Larson, I Scarfo, M Kann, A Schmidts, ...
JOURNAL FOR IMMUNOTHERAPY OF CANCER 8, A459-A459, 2020
12020
Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
M Wehrli, S Guinn, F Birocchi, A Kuo, Y Sun, RC Larson, AJ Almazan, ...
Clinical Cancer Research 30 (9), 1859-1877, 2024
2024
Developing a lenalidomide-inducible safety switch for CAR T cell therapy
D Sarkar, W Lin, JY Kim, NH Knudsen, IC Lane, T Kienka, MC Kann, ...
Cancer Research 84 (6_Supplement), 6321-6321, 2024
2024
Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
RC Larson, MC Kann, C Graham, CW Mount, AP Castano, WH Lee, ...
Nature Communications 14 (1), 7509, 2023
2023
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20